Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme
Publication
, Journal Article
Vredenburgh, J; Desjardins, A; Reardon, D
Published in: American Journal of Hematology Oncology
April 1, 2008
Duke Scholars
Published In
American Journal of Hematology Oncology
ISSN
1542-9520
Publication Date
April 1, 2008
Volume
7
Issue
4
Citation
APA
Chicago
ICMJE
MLA
NLM
Vredenburgh, J., Desjardins, A., & Reardon, D. (2008). Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme. American Journal of Hematology Oncology, 7(4).
Vredenburgh, J., A. Desjardins, and D. Reardon. “Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme.” American Journal of Hematology Oncology 7, no. 4 (April 1, 2008).
Vredenburgh J, Desjardins A, Reardon D. Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme. American Journal of Hematology Oncology. 2008 Apr 1;7(4).
Vredenburgh, J., et al. “Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme.” American Journal of Hematology Oncology, vol. 7, no. 4, Apr. 2008.
Vredenburgh J, Desjardins A, Reardon D. Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme. American Journal of Hematology Oncology. 2008 Apr 1;7(4).
Published In
American Journal of Hematology Oncology
ISSN
1542-9520
Publication Date
April 1, 2008
Volume
7
Issue
4